Results 111 to 120 of about 196,164 (338)

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

open access: yesAdvanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li   +12 more
wiley   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

open access: yesAdvanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang   +10 more
wiley   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

open access: yesAdvanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang   +7 more
wiley   +1 more source

AB0534 TREATING SYSTEMIC LUPUS ERYTHEMATOSUS IN THE 21ST CENTURY: COMBINING RITUXIMAB WITH BELIMUMAB [PDF]

open access: bronze, 2023
B. Issayeva   +9 more
openalex   +1 more source

Exploring the Vasculitis‐Tumors Link: Epidemiological Patterns, Mechanistic Insights, and Clinical Implications

open access: yesAdvanced Science, EarlyView.
This review outlines association between vasculitis and malignancies and provides practical value for clinicians in distinguishing primary vasculitis from malignancy‐associated forms and optimizing patient surveillance, improving recognition of tumor‐associated vasculitis to reduce the risk of misdiagnosis, supporting more accurate clinical decision ...
Xiaofei Shi   +8 more
wiley   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

open access: yesAdvanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo   +5 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

The complexity of dementia development and its comorbidities: The collaborative cross‐mouse population for multivarious tasks approach

open access: yesAnimal Models and Experimental Medicine, EarlyView.
The increasing prevalence of dementia and related neurodegenerative diseases—including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis—poses a growing public health challenge. These conditions have traditionally been studied as isolated central nervous system disorders, but emerging evidence points to ...
Osayd Zohud   +3 more
wiley   +1 more source

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

open access: yesClinicoEconomics and Outcomes Research, 2010
Firas Badin, John HayslipUniversity of Kentucky, Markey Cancer Center, Lexington, KY, USAAbstract: Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent
Firas Badin, John Hayslip
doaj  

Home - About - Disclaimer - Privacy